Fresenius Kabi is a global health care company that specializes in life-saving medicines and technologies for infusion, transfusion and clinical nutrition.
Kabiven was approved by the U.S. Food and Drug Administration in August. It is an intravenously infused solution of lipids, dextrose, amino acids and electrolytes in a three-chamber bag that efficiently delivers these nutrients in volumes and concentrations that meet the nutritional needs of most patients.
Fresenius Kabi expects to introduce Perikabiven® in November. Perikabiven is another Fresenius Kabi PN product that was also approved by the FDA in August. Perikabiven is intended for peripheral intravenous administration. Outside the United States, Kabiven is sold in more than 85 countries and has been used to treat millions of patients since its initial marketing authorization in 1999.
Kabiven and Perikabiven three-chamber bags contain amino acids with electrolytes, dextrose and lipids (Intralipid® 20%). The design of the three-chamber bag keeps the macronutrients separate and shelf-stable (without refrigeration) until the bag is activated and the contents mixed together for patient use. The formula is intended to meet the daily nutritional requirements of broad patient populations.